Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr;100(4):548-551.
doi: 10.1002/ajh.27618. Epub 2025 Jan 31.

Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma

Joshua Richter  1 , Madhav V Dhodapkar  2 , Mengying Li  3 , Mina Awad  3 , Christian Hampp  3 , Kate Knorr  3 , Glenn Kroog  3 , Tito Roccia  3 , Naresh Bumma  4
Affiliations
Editorial

Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma

Joshua Richter et al. Am J Hematol. 2025 Apr.
No abstract available

PubMed Disclaimer

References

    1. C. Blimark, E. Holmberg, U. H. Mellqvist, et al., “Multiple Myeloma and Infections: A Population‐Based Study on 9253 Multiple Myeloma Patients,” Haematologica 100, no. 1 (2015): 107–113.
    1. F. Mazahreh, L. Mazahreh, C. Schinke, et al., “Risk of Infections Associated With the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis,” Blood Advances 7, no. 13 (2023): 3069–3074.
    1. P. Moreau, A. L. Garfall, N. van de Donk, et al., “Teclistamab in Relapsed or Refractory Multiple Myeloma,” New England Journal of Medicine 387, no. 6 (2022): 495–505.
    1. A. M. Lesokhin, M. H. Tomasson, B. Arnulf, et al., “Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM‐3 Trial Results,” Nature Medicine 29, no. 9 (2023): 2259–2267.
    1. N. Bumma, J. Richter, S. Jagannath, et al., “Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma,” Journal of Clinical Oncology 42, no. 22 (2024): 2702–2712.

Publication types

LinkOut - more resources